Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects

Next Previous
Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leronlimab (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PRO140
  • Sponsors CytoDyn

Most Recent Events

  • 18 Mar 2025 According to a CytoDyn media release, results in patients with multi-drug-resistant HIV was recently published by the Journal of Acquired Immune Deficiency Syndromes.
  • 01 Dec 2021 According to a CytoDyn media release, the company has completed submission of all the major sections of CMC modules to the USA FDA, some remaining supporting documentation will be submitted under Regional Information before the end of this week. This submission was made under rolling review consistent with guidance from the U.S. Food and Drug Administration (FDA). Only the clinical section remains to be submitted.
  • 16 Nov 2021 According to a CytoDyn media release, the company will file for expanded access use of leronlimab for a fee to MDR HIV patients who might need leronlimab urgently, possibly as soon as next week.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top